A Phase 3 interventional study of Tranexamic acid and Placebo in Postpartum Hemorrhage, sponsored by London School of Hygiene and Tropical Medicine. Recruiting at 1 site in Tanzania. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by London School of Hygiene and Tropical Medicine · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage — 8 open to participants now, 8 under way, 3 of them phase 3. Tranexamic Acid · Postpartum Hemorrhage.
Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, this one has the largest planned enrollment, is one of 4 that started in 2024, is one of 16 in phase 3, and was the 39th registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →8 of the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage are open now, in 8 countries. Recruiting first, the newest first:
Wolfson Medical Center · Sites in Israel
Ages 18–51 · Women only · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–50 · Women only
Aligarh Muslim University · Sites in India
Ages 18–45 · Women only
Inova Health Care Services · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
University Hospital, Bordeaux · Sites in France
Ages 18–65 · Women only
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 18 · Phase 4 11
First in 2009; this study’s year is marked. 4 started in 2024.
This study's planned enrollment of 40,000 is above the median of 148 across 362 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 198 across the 50 interventional studies. Of the 35 that completed or were terminated, 7 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 50 has an industry lead sponsor. The 10 most frequent:
London School of Hygiene and Tropical Medicine is the lead sponsor of 298 studies on the registry; 15 are open to participants now.
London School of Hygiene and Tropical Medicine has 4 studies filed under Postpartum Hemorrhage — fewer than ten, so there is no comparison to draw.
4 of the studies testing Tranexamic Acid in Postpartum Hemorrhage that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04304625Phase 3University Hospital, BordeauxTRAnexamic Acid for Preventing Blood Loss Following a Cesarean Delivery in Women With Placenta pREVIA | 2027-06 |
| NCT05562609Phase 3London School of Hygiene and Tropical MedicineTranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher Risk | 2027-09 |
| NCT06754371RenJi HospitalProphylactic Tranexamic Acid Reduces Postpartum Hemorrhage | 2027-01 |
| NCT05370820Inova Health Care ServicesPrevention of Postpartum Hemorrhage With Tranexamic Acid | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Heavy bleeding after childbirth, known as a postpartum haemorrhage (PPH), causes about 70,000 maternal deaths every year. Tranexamic acid (TXA) is a lifesaving treatment for women with PPH. The I'M WOMAN trial is a research study to see whether giving TXA just before childbirth will stop women developing PPH. The trial will assess the effects of intramuscular (IM) and intravenous (IV) tranexamic acid on PPH, side effects and other important maternal health outcomes.
Postpartum haemorrhage (PPH) causes about 70,000 maternal deaths every year. Tranexamic acid (TXA) is a lifesaving treatment for women with PPH. The WOMAN trial recruited over 20,000 women with PPH and found that intravenous (IV) TXA given soon after PPH onset, reduces bleeding deaths by about a third. Early TXA also reduces blood loss in surgery and death due to bleeding after traumatic injury. The World Health Organization recommends that all women with PPH should receive TXA as a first line treatment.
TXA is more effective when given soon after the bleeding starts. Every fifteen minute delay reduces the survival benefit by about 10%. This suggests that giving TXA around the time of childbirth might prevent PPH. Although several clinical trials have examined the effectiveness of TXA for the prevention of PPH, the results are inconclusive. Trials of tranexamic acid for PPH prevention give the trial treatment after cord clamping, which may be too late to prevent bad bleeding in some women, as bleeding tends to happen soon after childbirth. Because PPH only affects a small proportion of births, the healthcare community need good evidence on the balance of benefits and harms in this population before using TXA to prevent PPH.
The I'M WOMAN trial will evaluate the effects of TXA for PPH prevention in women with one or more risk factors for PPH having a vaginal or caesarean birth. The trial will also evaluate the effect of the route of TXA administration. TXA is usually given by slow IV injection. However, recent research shows that TXA is well tolerated and rapidly absorbed after IM injection, achieving therapeutic blood levels within minutes of injection. There may be fewer side effects with IM TXA because peak blood concentrations are lower than with the IV route, as well as practical advantages.
The criteria were revised on the registry on Nov 4, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1g TXA as 2 x 5 ml IM injections (100mg/ml) and slow IV injection of placebo (1 x 10 ml of 0.9% sodium chloride)
Drug: Tranexamic acid · Other: Placebo
1g TXA by slow IV injection and 2 x 5 ml IM injections of placebo
Drug: Tranexamic acid · Other: Placebo
Placebo by 1 x slow 10ml IV injection and 2 x 5 ml IM injections
Other: Placebo
Ampoules and packaging for all arms will be identical in appearance.
Also known as: Cyklokapron
Ampoules and packaging for all arms will be identical in appearance.
Also known as: (Sodium Chloride 0.9%)
Risk of Postpartum haemorrhage
Clinical assessment: This may be an estimated blood loss of more than 500 mL in vaginal births or more than 1000 ml in caesarean births, or any blood loss sufficient to compromise haemodynamic stability. Haemodynamic instability is based on clinical judgement and assessed using clinical signs (low systolic blood pressure, tachycardia, reduced urine output)
Time frame: within 24 hours of childbirth
Intraoperative blood loss (caesarean births only)
Measured by quantifying the amount of blood in sponges and drapes used in surgery and blood loss from suctioning, excluding amniotic fluid
Time frame: During surgery
Surgery duration (caesarean births only)
Measured using patient records
Time frame: During surgery
Intraoperative whole blood/red cell transfusion (caesarean births only)
Measured using patient records
Time frame: During surgery
Bleeding related death or near miss (key secondary outcome)
Any of the following: * Death due to bleeding within 24 hours of birth * Measured blood loss ≥1500ml, comprising intraoperative and drape-measured blood loss up to 2 hours after the end of CS surgery or vaginal birth * Peripartum Hb drop ≥25g/L within 24 hours of birth * Surgical intervention for bleeding (hysterectomy, laparotomy, embolization, uterine compression sutures, arterial ligation) within 24 hours of birth * Blood transfusion of ≥5 units intraoperatively and up to 24 hours after birth * Cardiovascular dysfunction (shock, cardiac arrest, continuous vasoactive drugs, severe hypoperfusion, severe acidosis, cardiopulmonary resuscitation) * Renal dysfunction (oliguria non-responsive to fluids or diuretics, dialysis for acute renal failure, severe acute azotemia)
Time frame: See description
Drape-measured postpartum blood loss
Measured using a calibrated obstetric drape starting immediately after vaginal birth or once the women are shifted to a bed in the observation area after CS surgery
Time frame: 1 hour postpartum, or up to 2 hours if bleeding continues after 1 hour and the woman remains in bed
Blood pressure and heart rate
Lowest recorded blood pressure reading and associated heart rate measured using patient records
Time frame: Up to 24 h after birth
Estimated postpartum blood loss
Time frame: Up to 24 h after birth
Estimated postpartum blood loss (women with clinical diagnosis of PPH only)
Time frame: At time of PPH diagnosis
Haemoglobin (Hb) or haematocrit (Hct)/packed cell volume (PCV), white cell count, platelet count
Time frame: Up to 24 h after birth
Interventions for bleeding (uterotonics, non-trial TXA, blood transfusion, surgical and nonsurgical interventions)
Measured using patient records
Time frame: Up to 24 h after birth
Nausea, vomiting, dizziness
Time frame: At removal of calibrated drape
Pain or adverse skin reactions at injection sites
Time frame: At removal of calibrated drape
Prespecified maternal adverse events (thromboembolic events, seizure, sepsis, organ dysfunction, coagulopathy)
Measured using patient records
Time frame: Up to discharge, death or 42 days postpartum, whichever is first.
Other maternal adverse events
Measured using patient records
Time frame: Up to discharge, death or 42 days postpartum, whichever is first.
Maternal mortality
All-cause, cause-specific, narrative; Measured using patient records
Time frame: Up to discharge, death or 42 days postpartum, whichever is first.
Length of hospital stay
Measured using patient records
Time frame: Up to discharge, death or 42 days postpartum, whichever is first.
Days in ICU/HDU
Measured using patient records
Time frame: Up to discharge, death or 42 days postpartum, whichever is first.
Transfer to another hospital
Measured using patient records
Time frame: Up to discharge, death or 42 days postpartum, whichever is first.
Prespecified neonatal outcomes (breastfeeding, intracranial haemorrhage, pulmonary haemorrhage, bruising, thromboembolic event, seizure, stillbirth/intrapartum death, neonatal death, cause of death, congenital and genetic abnormalities, adverse events)
Measured using patient records
Time frame: Up to discharge, death or 42 days postpartum, whichever is first.
Plan to share: Yes — The investigators are committed to sharing data for ethical research with justified scientific objectives. Until all planned analyses are completed by the LSHTM CTU Global Health Trials Group, data will be shared through a controlled access approach whereby researchers can make formal applications for data sharing. Afterwards, the anonymised dataset will be shared via the LSHTM CTU Global Health Trials Group data sharing platform at freebird.lshtm.ac.uk. All trial materials including training materials, CRFs and Protocol will be made available on the trial website and team YouTube channel.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Once all planned analyses are completed by the LSHTM CTU Global Health Trials Group following trial completion. Data will be shared indefinitely.
Access criteria: As above
Data sharing details ↗ · freebird.lshtm.ac.uk
Started Apr 2024 (actual). Primary completion is estimated for Sep 2027, 41 months after the start.
Of 20 phase 3 interventional studies under Postpartum Hemorrhage, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 41 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Aug 2025 → Sep 2027 and completion Sep 2025 → Oct 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
London School of Hygiene and Tropical Medicine →